Top

memo - Magazine of European Medical Oncology

Published in:

Open Access 01-02-2017 | short review

Milestones in pathology—from histology to molecular biology

Author: Dr. Leonhard Müllauer

Published in: memo - Magazine of European Medical Oncology | Issue 1/2017

Summary

Autopsy, histology and cytology have been and histology and cytology still are the main diagnostic tools in surgical pathology. During the last two decades molecular biology gradually has extended the diagnostic armamentarium. In tumor pathology molecular biology techniques are used to diagnose and subclassify tumors, predict response to therapies and identify therapeutic targets. Molecular pathology has evolved into a novel focus of clinical pathology and transforms the historically morphology based discipline. Traditional pathology and molecular pathology combine and guide tumor therapy.

de Matos LL, Trufelli DC, de Matos MGL, da Silva Pinhal MA. Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark Insights. 2010;5:9–20.CrossRefPubMedPubMedCentral

Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112(13):4808–17. doi:10.1182/blood-2008-07-077958.CrossRefPubMed

Moasser MM, Krop IE. The evolving landscape of HER2 targeting in breast cancer. JAMA Oncol. 2015;1(8):1154–61. doi:10.1001/jamaoncol.2015.2286.CrossRefPubMed

Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to Gefitinib therapy. Science. 2004;304(5676):1497–500. doi:10.1126/science.1099314.CrossRefPubMed

Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101(36):13306–11.CrossRefPubMedPubMedCentral

Buermans HP, den Dunnen JT. Next generation sequencing technology: advances and applications. Biochim Biophys Acta. 2014;1842(10):1932–41. doi:10.1016/j.bbadis.2014.06.015.CrossRefPubMed

Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet. 2013;14(10):703–18. doi:10.1038/nrg3539.CrossRefPubMedPubMedCentral

Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–9. doi:10.1038/nature12634.CrossRefPubMedPubMedCentral

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58. doi:10.1126/science.1235122.CrossRefPubMedPubMedCentral

10.

Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001;291(5507):1304–51. doi:10.1126/science.1058040.CrossRefPubMed

11.

Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921. doi:10.1038/35057062.CrossRefPubMed

12.

Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1a):A68–77. doi:10.5114/wo.2014.47136.

13.

Birney E, Soranzo N. Human genomics: the end of the start for population sequencing. Nature. 2015;526:52–3. doi:10.1038/526052a.CrossRefPubMed

14.

Harrington CT, Lin EI, Olson MT, Eshleman JR. Fundamentals of pyrosequencing. Arch Pathol Lab Med. 2013;137(9):1296–303. doi:10.5858/arpa.2012-0463-RA.CrossRefPubMed

15.

Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023–31. doi:10.1038/nbt.2696.CrossRefPubMed

16.

Diaz LA Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–86. doi:10.1200/JCO.2012.45.2011.CrossRefPubMedPubMedCentral

17.

Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12(5):323–34.CrossRefPubMed

18.

Do H, Dobrovic A. Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clin Chem. 2015;61(1):64–71. doi:10.1373/clinchem.2014.223040.CrossRefPubMed

19.

Hudecova I. Digital PCR analysis of circulating nucleic acids. Clini Biochem. 2015;48(15):948–56. doi:10.1016/j.clinbiochem.2015.03.015.CrossRef

20.

Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA. 2011;108(23):9530–5. doi:10.1073/pnas.1105422108.CrossRefPubMedPubMedCentral

21.

Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560–2. doi:10.1038/nm.3854.CrossRefPubMedPubMedCentral

22.

Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4(6):650–61. doi:10.1158/2159-8290.cd-13-1014.CrossRefPubMedPubMedCentral

Title: Milestones in pathology—from histology to molecular biology
Author: Dr. Leonhard Müllauer
Publication date: 01-02-2017
Publisher: Springer Vienna
Published in: memo - Magazine of European Medical Oncology / Issue 1/2017
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-016-0307-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 1/2017

Milestones of the last 10 years

memo: Official journal of the OeGHO and CECOG

Milestones in advanced renal cell carcinoma

Milestones in gastric cancer

My personal highlights of ESMO 2016

Milestones in Chronic Lymphocytic Leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer